Biotest AG
ISIN: DE0005227235
WKN: 522723
02 October 2024 02:00PM

EQS-News: Strategic agreement signed for distribution of Yimmugo® in the United States based on the framework established in July

Biotest AG · ISIN: DE0005227235 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2000717

EQS-News: Biotest AG / Key word(s): Market Launch
Strategic agreement signed for distribution of Yimmugo® in the United States based on the framework established in July

02.10.2024 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

PRESS RELEASE

 

 

Strategic agreement signed for distribution of Yimmugo® in the United States based on the framework established in July

 

  • All contractual terms finalized and definitive agreement with Kedrion signed
  • Expected to generate revenues of more than $1 billion for Biotest during the 7-year term
  • Preparations for U.S. launch of Yimmugo® in 2025 well underway

 

Dreieich, Germany, October 2, 2024. Following the agreement of binding terms in July, the parties have now finalized all contractual terms and Biotest, part of the Grifols Group, has entered into a long-term agreement with Kedrion Biopharma Inc., Fort Lee (NJ), USA, for the full commercialization and distribution of its immunoglobulin Yimmugo® in the United States.

The distribution agreement requires Biotest to supply and Kedrion to purchase minimum quantities of Yimmugo® over the seven-year term, representing approximately $1 billion in sales for Biotest. This agreement represents Biotest's largest commercial agreement since its founding.

Production of the quantities needed to enter the United States began immediately after the Biologic License Application (BLA) was approved and is ongoing. Preparations for the market launch of the product in 2025 have already begun and are now in full preparation.

With Yimmugo®, a Biotest product is entering a U.S. market which, with more than 100 tons and annual IVIG sales of $10 billion, represents the most important market for the plasma derivatives sector.

 

 

 

About Yimmugo® (IgG Next Generation)

Yimmugo® is a newly developed polyvalent immunoglobulin G preparation from human blood plasma for intravenous administration (IVIg). The sugar-free ready-to-use solution is approved in European markets for substitution therapy in primary antibody deficiency syndromes and secondary immune deficiency, as well as for immunomodulation in autoimmune diseases such as ITP, GBS, CIDP, MMN and Kawasaki syndrome. Under the U.S. license Biotest is authorized to manufacture Yimmugo® for the treatment of primary humoral deficiency (PI) in patients 2 years of age or older. Yimmugo® is the first approved product from Biotest's new Next Level production facility. The modern production process stands for highest product quality and responsible use of resources.

 

About Biotest

Biotest (www.biotest.com) is a provider of biological therapeutics derived from human plasma. With a value-added chain that extends from preclinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, hematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German Stock Exchange. Since May 2022, Biotest has been a part of the Grifols Group, headquartered in Barcelona, Spain (www.grifols.com).

 

 

IR contact

Dr Monika Baumann (Buttkereit)

Phone: +49-6103-801-4406
Mail: ir@biotest.com

 

PR contact

Dirk Neumüller

Phone: +49-6103-801-269
Mail: pr@biotest.com

 

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

 

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201

Preference shares: securities’ ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

 

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

 



02.10.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-767
E-mail: ir@biotest.com
Internet: www.biotest.com
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2000717

 
End of News EQS News Service

2000717  02.10.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2000717&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 400,30 419,10 484,20 515,60 516,10 684,60 743,00
EBITDA1,2 35,20 30,50 28,30 -16,10 19,20 179,40 128,00
EBITDA-Margin3 8,79 7,28 5,85 -3,12 3,72 26,21 17,23
EBIT1,4 10,60 -1,20 -1,30 -47,10 -16,60 143,50 92,00
EBIT-Margin5 2,65 -0,29 -0,27 -9,14 -3,22 20,96 12,38
Net Profit (Loss)1 181,70 -4,70 -31,40 -63,40 -31,70 127,00 35,00
Net-Margin6 45,39 -1,12 -6,49 -12,30 -6,14 18,55 4,71
Cashflow1,7 -50,00 -33,60 -16,70 33,90 -40,50 -2,70 0,00
Earnings per share8 4,58 -0,11 -0,72 1,59 -0,79 3,22 0,88
Dividend per share8 0,04 0,04 0,04 0,04 0,00 0,08 0,04
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: KPMG

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Biotest VZ
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
522723 DE0005227235 AG 1.329,60 Mio € 14.10.1987 Halten 9F2C2M4X+6R
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
24,34 17,09 1,42 138,71 2,05 -378,13 1,94
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,00 0,08 0,04 0,16%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
07.05.2024 07.05.2024 30.07.2024 05.11.2024 28.03.2025
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
-1,53%
25,80 €
ATH 44,50 €
-4,95% -5,11% -16,77% -16,77% +149,76%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL